APOA1 and atherosclerosis: Despite extensive efforts, including the recent Phase III AEGIS-II trial of a novel apolipoprotein A-I (ApoA-I) formulation [6], clinical success in reducing ASCVD by enhancing HDL biogenesis and function remains elusive.